EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

PURPOSE: To assess the safety/tolerability and antitumor activity of enfortumab vedotin (EV), a novel investigational antibody-drug conjugate that delivers the microtubule-disrupting agent, monomethyl auristatin E, to cells that express Nectin-4. METHODS: EV-101 is a phase I dose escalation/expansio...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Clin Oncol
Huvudupphovsmän: Rosenberg, Jonathan, Sridhar, Srikala S., Zhang, Jingsong, Smith, David, Ruether, Dean, Flaig, Thomas W., Baranda, Joaquina, Lang, Joshua, Plimack, Elizabeth R., Sangha, Randeep, Heath, Elisabeth I., Merchan, Jamie, Quinn, David I., Srinivas, Sandy, Milowsky, Matthew, Wu, Chunzhang, Gartner, Elaina M., Zuo, Peiying, Melhem-Bertrandt, Amal, Petrylak, Daniel P.
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Clinical Oncology 2020
Ämnen:
ORIGINAL REPORTS
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7106979/
https://ncbi.nlm.nih.gov/pubmed/32031899
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.02044
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk